Was the Mineralys (MLYS) CEO’s share sale part of a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on December 30, 2025 . Such plans pre-schedule trades, indicating this sale followed a pre-arranged program rather than being a spur-of-the-moment market decision.

Mineralys (MLYS) CEO sells 15,730 shares in Rule 10b5-1 stock plan trade

Q: What insider transaction did Mineralys Therapeutics (MLYS) report for its CEO?

Mineralys Therapeutics reported that CEO Jon Congleton sold 15,730 shares of common stock in an open-market transaction. The sale occurred on April 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

Q: At what price did the Mineralys (MLYS) CEO sell his shares?

The CEO’s sale used a weighted-average price of $26.8264 per share. According to the disclosure, the shares were sold in multiple transactions at prices ranging from $26.81 to $26.96 , reflecting typical execution across several individual trades in the market.

Q: How many Mineralys (MLYS) shares does the CEO hold after this Form 4 sale?

After the reported sale, CEO Jon Congleton directly owns 689,321 shares of Mineralys common stock. This figure comes from the post-transaction holding column and shows that the sale represents only a portion of his total reported equity stake in the company.

Q: What does the weighted-average price mean in the Mineralys (MLYS) Form 4?

The filing notes the reported $26.8264 is a weighted-average price across several trades. Individual sales occurred between $26.81 and $26.96 . The insider offers to provide detailed trade-by-trade pricing information to the company, shareholders, or SEC staff upon request.

Q: Is the Mineralys (MLYS) CEO’s Form 4 sale a buy or sell transaction?

This Form 4 reflects a sale transaction. The coded transaction type is an open-market sale of common stock, with 15,730 shares sold and a resulting net-sell direction in the summary data, while the CEO continues to hold a substantial remaining share position.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Executive Officer Jon Congleton reported an open-market sale of 15,730 shares of common stock on April 13, 2026 at a weighted-average price of $26.8264 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

Following this sale, Congleton directly holds 689,321 shares of Mineralys common stock, indicating that the transaction covers only a portion of his overall equity position. The shares were sold in multiple trades at prices ranging from $26.81 to $26.96.

Insider Trade Summary 10b5-1

Net Seller: 15,730 shares ($421,979)

Net Sell 1 txn

Insider Congleton Jon

Role Chief Executive Officer

Sold 15,730 shs ($422K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,730	$26.8264	$422K

Holdings After Transaction: Common Stock — 689,321 shares (Direct)

Footnotes (1)

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $26.96. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Key Figures

Shares sold: 15,730 shares Weighted-average sale price: $26.8264 per share Post-sale holdings: 689,321 shares +2 more

5 metrics

Shares sold 15,730 shares Open-market sale on April 13, 2026

Weighted-average sale price $26.8264 per share Common stock sale transactions

Post-sale holdings 689,321 shares CEO direct ownership after transaction

Price range of trades $26.81–$26.96 per share Individual trade prices within the sale

Net buy/sell shares -15,730 shares Net-sell direction in transaction summary

Key Terms

Rule 10b5-1 trading plan, weighted-average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

open-market sale financial

"transaction_action is classified as an open-market sale of Common Stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 09:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last)

(First)

(Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR

PENNSYLVANIA

19087

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/13/2026		S⁽¹⁾		15,730	D	$26.8264⁽²⁾	689,321	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.81 to $26.96. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Mineralys Therapeutics (MLYS) report for its CEO?

Mineralys Therapeutics reported that CEO Jon Congleton sold 15,730 shares of common stock in an open-market transaction. The sale occurred on April 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.

At what price did the Mineralys (MLYS) CEO sell his shares?

The CEO’s sale used a weighted-average price of $26.8264 per share. According to the disclosure, the shares were sold in multiple transactions at prices ranging from $26.81 to $26.96, reflecting typical execution across several individual trades in the market.

How many Mineralys (MLYS) shares does the CEO hold after this Form 4 sale?

After the reported sale, CEO Jon Congleton directly owns 689,321 shares of Mineralys common stock. This figure comes from the post-transaction holding column and shows that the sale represents only a portion of his total reported equity stake in the company.

What does the weighted-average price mean in the Mineralys (MLYS) Form 4?

The filing notes the reported $26.8264 is a weighted-average price across several trades. Individual sales occurred between $26.81 and $26.96. The insider offers to provide detailed trade-by-trade pricing information to the company, shareholders, or SEC staff upon request.

Is the Mineralys (MLYS) CEO’s Form 4 sale a buy or sell transaction?

This Form 4 reflects a sale transaction. The coded transaction type is an open-market sale of common stock, with 15,730 shares sold and a resulting net-sell direction in the summary data, while the CEO continues to hold a substantial remaining share position.